Individualizing Treatment with New & Emerging Therapies

Volume 2, Issue 5

Individualizing Treatment with New & Emerging Therapies

In this issue:

Personalizing treatment for patients with MS is hugely challenging. To be successful, clinicians need to balance many factors - an unpredictable disease course with unpredictable relapse rates, idiosyncratic drug reactions, lesion topography and severity - for every patient. What can help clinicians better manage this juggling act?

In this issue, Drs. Daniel Ontaneda, Jenny Feng, and Gabrielle Macaron from the Cleveland Clinic analyze recent publications describing the effects new and emerging treatment options may have on individualizing MS therapy.

Learning objectives:

Describe personalized therapy based on predictors of disease worsening and the risk profile of particular therapy options.
Explain the need for more effective agents in treating progressive MS.
Summarize the recently published trials of therapies for progressive MS.

Authors:

Jenny Feng, MD

Neuroimmunology Fellow
Cleveland Clinic Neurological Institute
Cleveland, OH

Daniel Ontaneda, MD

Staff Neurologist
Cleveland Clinic Neurological Institute
Cleveland, OH

Gabrielle Macaron, MD

Neuroimmunology Fellow
Cleveland Clinic Neurological Institute
Cleveland, OH

Guest Faculty Disclosures

Dr. Feng has disclosed that she has served on an advisory board for Sanofi-Aventis. She also receives Sylvia Lawry fellowship funding from the National MS Society.

Dr. Ontaneda has disclosed that he has acted as a consultant for Novartis AG, Biogen Inc., and Genentech, Inc. and has performed contracted research and received research funds from Genentech, Inc., Genzyme Corporation, and Novartis AG.

Dr. Macaron has disclosed that she has served on a scientific advisory board for Genentech. She previously received fellowship funding from Biogen Inc and currently receives fellowship funding through the National MS Society.

Unlabeled/Unapproved Uses

The authors have indicated that they will be referencing the unlabeled/unapproved uses of cladribine, ofatumumab, simvastatin, ibudilast, and siponimod for the treatment of MS.

Program Director:

Michael Kornberg, MD, PhD

Assistant Professor
Department of Neurology
Johns Hopkins School of Medicine
Baltimore, MD

Guest Faculty Disclosures:

Dr. Feng has disclosed that she has served on an advisory board for Sanofi-Aventis. She also receives Sylvia Lawry fellowship funding from the National MS Society.

Unlabeled/Unapproved Uses:

The authors have indicated that they will be referencing the unlabeled/unapproved uses of cladribine, ofatumumab, simvastatin, ibudilast, and siponimod for the treatment of MS.

Length of activity:

1.0 hour Physicians

Launch date: May 18, 2019
Expiration date: May 17, 2021

Start Issue